Last Update 23 Jun 26
Fair value Decreased 1.71%GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00.
Analyst Commentary
Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates. For you as an investor, the key takeaway is that expectations are being fine tuned rather than completely reset.
Bullish Takeaways
- Bullish analysts see the updated €10 target as consistent with a view that Grifols can still justify its current valuation if it executes reliably on its existing business plan.
- The decision to keep coverage in place, rather than withdraw it, suggests continued interest in Grifols as a viable listed plasma and healthcare company.
- Maintaining a neutral rating alongside the revised target indicates that, in bullish analysts' view, the stock offers a balance between upside potential and execution risk at current prices.
Bearish Takeaways
- Bearish analysts interpret the €1 cut in the Street level targets to around €10 as a sign that prior expectations for Grifols' earnings power may have been too optimistic.
- The reduced fair value assumptions point to concerns that Grifols may face tighter profitability or higher required returns, which can weigh on valuation multiples.
- A Hold stance, rather than a more positive rating, implies that some analysts see limited room for re rating without clearer evidence on execution or margin resilience.
- Overall, the lower target range signals that bearish analysts view the risk or reward trade off for Grifols as more finely balanced than before, warranting careful position sizing.
What’s in the News for Grifols
- Grifols has launched FESILTY, an FDA approved, highly purified human fibrinogen concentrate in the U.S. for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, expanding its plasma derived medicines portfolio for bleeding disorders. Source: company announcement, Phase I/III clinical data.
- FESILTY is positioned as a more targeted option compared with cryoprecipitate and fresh frozen plasma, offering a precisely defined fibrinogen dose, room temperature storage at the point of care, and reconstitution in about three minutes. This can be relevant for hospitals assessing treatment logistics and product mix. Source: product related announcement.
- Clinical results supporting FESILTY were published in Thrombosis and Haemostasis and Thrombosis Research, with data cited on pharmacokinetics, hemostatic efficacy, safety, and identified risks such as thrombotic events and hypersensitivity reactions. This information may give investors more visibility into the evidence base behind this new Grifols therapy. Source: referenced clinical study NCT02065882.
- At the Ordinary General Shareholders' Meeting held on June 18, 2026, Grifols shareholders approved amendments to the company’s Articles of Association. These changes may signal corporate governance and bylaw updates that investors may want to review once detailed documentation is available. Source: company key developments.
- The same June 18, 2026 board meeting agenda included proposals to re elect Mrs. Montserrat Muñoz Abellana and Mrs. Susana González Rodríguez to key committee roles, which may interest investors who closely track Grifols’ board composition and oversight of remuneration, audit, and sustainability topics. Source: company key developments.
Valuation Changes for Grifols
- Fair Value was trimmed slightly from €14.65 to €14.40, indicating a small reduction in the modeled equity value per share.
- The Discount Rate increased from 10.74% to 11.01%, implying a modestly higher required return applied to Grifols in updated models.
- Revenue Growth eased from 5.93% to 5.57%, reflecting slightly lower projected € revenue expansion in future periods.
- Net Profit Margin was adjusted marginally from 10.11% to 10.08%, signaling a very small change in expected € earnings retained from each euro of sales.
- Future P/E moved from 15.13x to 15.18x, a minimal shift that leaves the implied earnings multiple on Grifols broadly unchanged.
2 viewsusers have viewed this narrative update
Key Takeaways
- Expanding plasma therapies, pipeline innovation, and entry into new markets are supporting sustained growth and margin improvement.
- Investments in network efficiency and effective cost management are enabling better cash flow, balance sheet strength, and shareholder returns.
- Ongoing pricing pressure, currency volatility, operational risks, rising competition from alternatives, and high debt collectively threaten Grifols' profitability, growth, and financial flexibility.
Catalysts
About Grifols- Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
- Robust global demand for plasma-derived therapies is driving above-market revenue growth for Grifols' core immunoglobulin, albumin, and alpha-1 franchises, a trend supported by increased disease prevalence from an aging population and rising diagnosis rates, which is expected to support sustained revenue expansion.
- Grifols' investments in expanding and optimizing its global plasma collection network, combined with advanced process innovations (e.g., nomogram adoption and digitalization), are boosting plasma volumes and operating efficiencies-translating into improved gross and EBITDA margins, supporting future earnings growth.
- Accelerated progress in Grifols' innovation pipeline-including key milestones like the upcoming launches of new products (notably fibrinogen in Europe and the US), expansion of IG indications, and new specialty therapies-are expected to unlock new revenue streams and further margin upside over time.
- Ongoing expansion into emerging and underpenetrated markets (such as China and Canada), aided by strategic alliances and localized manufacturing/distribution, is growing Grifols' addressable market, diversifying revenue sources, and supporting long-term top-line growth.
- Disciplined cost management, deleveraging efforts, and normalization of business operations are strengthening Grifols' balance sheet and enabling higher free cash flow generation, supporting reinvestment and the resumption of shareholder returns, positively impacting net margins and overall earnings quality.
Grifols Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Grifols's revenue will grow by 5.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from 5.6% today to 10.1% in 3 years time.
- Analysts expect earnings to reach €882.1 million (and earnings per share of €1.42) by about June 2029, up from €415.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €993.5 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.2x on those 2029 earnings, up from 14.8x today. This future PE is greater than the current PE for the GB Biotechs industry at 14.8x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 11.01%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Continued pricing pressure in key markets like China, resulting from government efforts to reduce healthcare and pharmaceutical costs, could undermine revenue growth and compress net margins for Grifols' albumin and other plasma-derived products.
- Persistent currency volatility, particularly US dollar depreciation, poses an ongoing headwind to reported revenues and EBITDA, and while currently mitigated by natural hedges, future changes could negatively impact earnings, especially as the company's costs and revenues are exposed to multiple currencies.
- The company remains highly dependent on plasma collection centers, leaving it exposed to risk from operational disruptions, regulatory changes, labor shortages, and rising collection costs, all of which could materially jeopardize reliable revenue streams and impact long-term earnings growth.
- Grifols faces increasing long-term competition from emerging alternative therapies such as gene therapies, recombinant products, and synthetic biologics, which may gradually erode demand for plasma-based therapies and limit future revenue and market share expansion.
- High leverage and a significant debt servicing burden continue to limit Grifols' financial flexibility; while deleveraging is underway, elevated debt levels expose the company to risks from rising interest rates and leave less room for investments in R&D and innovation, potentially impacting future net margins and earnings growth.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €14.4 for Grifols based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €21.2, and the most bearish reporting a price target of just €9.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €8.8 billion, earnings will come to €882.1 million, and it would be trading on a PE ratio of 15.2x, assuming you use a discount rate of 11.0%.
- Given the current share price of €9.03, the analyst price target of €14.4 is 37.3% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Grifols?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
€21.2
FV
54.0% undervalued intrinsic discount7.77%
Revenue growth p.a.
69
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
€9
FV
8.2% overvalued intrinsic discount5.32%
Revenue growth p.a.
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative